Spyre Therapeutics, Inc. 8-K

What Happened

• On June 15, 2026, Spyre Therapeutics (SYRE) announced via Form 8-K and press release that SPY002 met all key objectives in Part A (12-week induction) of the Phase 2 SKYLINE trial in moderately-to-severely active ulcerative colitis (UC). The primary endpoint showed a statistically significant 10.7‑point reduction in the Robarts Histopathology Index (RHI) from baseline (p<0.0001). The company reported a 33% clinical remission rate, 42% endoscopic improvement rate, and a mean change in modified Mayo Score (mMS) of −3.7.

Key Details

• Trial context: Part A population (SPY002 n=48) included 35% advanced therapy‑exposed patients, mean disease duration 7.0 years, mean baseline RHI 16.9 ± 8.5, mean baseline mMS 6.9 ± 1.0, and 56% had baseline endoscopy score of 3.
• Primary efficacy: Change in RHI −10.7 (p<0.0001). Clinical remission 33%; endoscopic improvement 42%; mMS change −3.7 at Week 12.
• Safety: 20 subjects (41.7%) experienced any treatment‑emergent AE; 2 severe AEs (4.2%); 3 drug‑related AEs (6.3%); 2 AEs led to discontinuation (4.2%); 2 SAEs reported (4.2%), both deemed not drug‑related. No deaths or drug‑related SAEs reported. Most common AEs (≥2 patients): hypertension (3), arthralgia (2), nausea (2), UC (2), viral respiratory infection (2).
• Disclosure: Results announced via press release and disclosed under Regulation FD in the Form 8‑K filed June 15, 2026.

Why It Matters

• These are early but positive Phase 2 topline results showing strong histologic and clinical signals for SPY002 in UC, including a highly significant improvement in RHI and meaningful clinical remission and endoscopy rates. For investors, the data represent a clinical milestone and potential program de‑risking event, while safety appears consistent with the company’s TL1A class profile. Next investor items to watch (per typical development timelines) include full data disclosure, longer‑term outcomes, Part B results, and regulatory strategy updates.